Palbociclib (P) in patients (Pts) with pancreatic cancer (PC) and gallbladder or bile duct cancer (GBC) with CDKN2A alterations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.


Conference Paper

Full Text

Duke Authors

Cited Authors

  • Al Baghdadi, T; Halabi, S; Garrett-Mayer, E; Mangat, PK; Ahn, ER; Sahai, V; Alvarez, RH; Kim, ES; Yost, KJ; Guo, K; Rygiel, AL; Antonelli, KR; Butler, NL; Bruinooge, SS; Schilsky, RL

Published Date

  • May 20, 2018

Published In

Volume / Issue

  • 36 / 15_suppl

Start / End Page

  • 2532 - 2532

Published By

Electronic International Standard Serial Number (EISSN)

  • 1527-7755

International Standard Serial Number (ISSN)

  • 0732-183X

Digital Object Identifier (DOI)

  • 10.1200/jco.2018.36.15_suppl.2532